Soe

I. BACKGROUND

22 Pursuant to the Complaint filed in this matter, Progenity is a biotechnology 23 company based in San Diego, California that “specializes in developing and 24 commercializing molecular testing products and precision medicine applications,” 25 including “in vitro molecular tests designed to assist parents in making informed 26 1 Document numbers and page references are to those assigned by CM/ECF for the docket entry. 2 On November 17, 2020, Phillip Matz filed a Notice of Non-Opposition to Competing Motions. [Doc. No. 26.] Accordingly, “Competing Motions” refers to the motions filed by the Lin group 28 decisions related to family planning, pregnancy, and complex disease diagnosis.” [Doc. No. 1 at p. 3, ¶ 4.] Plaintiff alleges that Progenity conducted its Initial Public Offering (“IPO”) on June 22, 2020,3 where Defendants sold over 6.6 million shares of Progenity common stock at a price of $15 per share, generating over $100 million in gross offering proceeds. [Id. at p. 3, ¶ 5.] On August 28, 2020, Plaintiff filed the present class action lawsuit against Progenity, certain of its officers and directors, and the…